This website uses tracking technologies, such as cookies, to provide a better user experience. If you continue to use this site, then you acknowledge our use of tracking technologies. For additional information, review our Privacy Policy.
Originally diagnosed in July 2016, Michelle’s treatment plan progressed very quickly, including chemotherapy, radiation therapy, and surgery. Her family and coworkers helped support her throughout treatment. Declared cancer-free by the end of December 2016, she considered her next steps to stay cancer-free. In February 2017, she met with Dr. Deirdre Cohen at at NYU Langone’s Perlmutter Cancer Center, who recommended Michelle enroll in a clinical trial of nivolumab (Opdivo®).
Today, Michelle looks forward to new adventures with her husband and daughter and a future immune to cancer.
Provide guidance and encouragement to others going through their journey with cancer immunotherapy treatment.
Contact Us
Cancer Research Institute | National Headquarters 29 Broadway, Floor 4 | New York, NY 10006-3111
800-992-2623212-832-9376Staff Directory
This September for Childhood Cancer Awareness Month, we look at new research, new treatments, and how we are working toward a future immune to childhood cancer.
This September for Gynecologic Cancer Awareness Month, we reflect on new treatments, research discoveries, and how CRI is making its impact on a future immune to cervical, ovarian, and uterine cancers.
